Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00243451 · ClinicalTrials.gov registry record

Early Detection of Mild Cognitive Impairment in Individual Patients

A clinical trial of Mild Cognitive Impairment and Mild Alzheimer's Disease, sponsored by Louisiana State University Health Sciences Center Shreveport.

Completed
Registry status
34
Enrollment target
1
Study location

NCT00243451: Completed study of Mild Cognitive Impairment and Mild Alzheimer's Disease, sponsored by Louisiana State University Health Sciences Center Shreveport.

NCT00243451 is a study of Mild Cognitive Impairment and Mild Alzheimer's Disease that has completed, run by Louisiana State University Health Sciences Center Shreveport. The registered enrollment target is 34 participants, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower). The trial reports 1 study location across 1 state. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00243451, a study of Mild Cognitive Impairment and Mild Alzheimer's Disease, has completed, sponsored by Louisiana State University Health Sciences Center Shreveport.

COMPLETED
Registry status
34 participants
Enrollment target
1
Study location

Study Summary

Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of \[18\]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.

Interventions

  • OTHER PET scan & fMRI

Study Locations (1)

Louisiana

  • Louisiana State University Health Sciences Center - Shreveport

Trial Details

FieldValue
Enrollment Target 34 participants
Start Date 2003-09
Est. Completion 2011-07

What the finished NCT00243451 record still lists

NCT00243451 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 34 participants, a relatively small participant target, below the 1,270-participant average among 205 other Mild Cognitive Impairment trials with a reported enrollment target (97% lower).

The record links to 2 conditions, with Mild Cognitive Impairment appearing as the primary indexed condition, and to 1 intervention - of which PET scan & fMRI is the first listed.

NCT00243451 reports a single indexed study location in Louisiana.

Frequently Asked Questions

What is clinical trial NCT00243451 about?

NCT00243451 is a clinical study titled "Early Detection of Mild Cognitive Impairment in Individual Patients". Our central hypothesis is that the early metabolic lesions of MCI can be reliably detected in individual subjects by objective analysis of \[18\]F-fluorodeoxyglucose (FDG) positron-emission tomography (PET) brain images, earlier and more accurately than by subjective clinician rating.

What is the current status of trial NCT00243451?

This trial is currently completed. The enrollment target is 34 participants. The study started on 2003-09. Estimated completion is 2011-07.

What conditions does trial NCT00243451 study?

This clinical trial studies the following conditions: Mild Cognitive Impairment, Mild Alzheimer's Disease.

What interventions are being tested in trial NCT00243451?

The interventions under investigation include: PET scan & fMRI (OTHER).

Who is sponsoring clinical trial NCT00243451?

This trial is sponsored by Louisiana State University Health Sciences Center Shreveport, which has 40 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00243451 being conducted?

This trial has 1 study location across Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Similar trials for Mild Cognitive Impairment

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00243451's enrollment target sits among peer trials

34 161st of 205 higher than 44 of 205 other Mild Cognitive Impairment trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Mild Cognitive Impairment trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT02897063 · 34 participants · Phase 1

    Effects of Midodrine and Droxidopa on Splanchnic Capacitance in Autonomic Failure

  • NCT03906617 · 34 participants · Phase 4

    Bupivacaine/Epinephrine +Dexamethasone vs. Liposomal Bupivacaine

  • NCT03992378 · 34 participants · NA

    Neuromodulation to Regulate Inflammation and Autonomic Imbalance in Sepsis

  • NCT04047849 · 34 participants · Phase 4

    Latency Antibiotics in Previable PPROM, 18 0/7- 22 6/7 WGA

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Source: ClinicalTrials.gov NCT00243451, the US trial registry maintained by the National Library of Medicine. NCT00243451 (small enrollment · single site footprint · completed) retrieved and formatted by PlainTrial, see methodology.